Food-Derived Compounds Apigenin and Luteolin Modulate mRNA Splicing of Introns with Weak Splice Sites

• Published in: iScience Vol. 22; pp. 336 - 352
• Main Authors: Kurata, Masashi, Fujiwara, Naoko, Fujita, Ken-ichi, Yamanaka, Yasutaka, Seno, Shigeto, Kobayashi, Hisato, Miyamae, Yusaku, Takahashi, Nobuyuki, Shibuya, Yasuyuki, Masuda, Seiji
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 20.12.2019; Elsevier
• Subjects: Molecular Biology; Molecular Biology
• ISSN: 2589-0042; 2589-0042
• DOI: 10.1016/j.isci.2019.11.033

Cancer cells often exhibit extreme sensitivity to splicing inhibitors. We identified food-derived flavonoids, apigenin and luteolin, as compounds that modulate mRNA splicing at the genome-wide level, followed by proliferation inhibition. They bind to mRNA splicing-related proteins to induce a widespread change of splicing patterns in treated cells. Their inhibitory activity on splicing is relatively moderate, and introns with weak splice sites tend to be sensitive to them. Such introns remain unspliced, and the resulting intron-containing mRNAs are retained in the nucleus, resulting in the nuclear accumulation of poly(A)+ RNAs in these flavonoid-treated cells. Tumorigenic cells are more susceptible to these flavonoids than nontumorigenic cells, both for the nuclear poly(A)+ RNA-accumulating phenotype and cell viability. This study illustrates the possible mechanism of these flavonoids to suppress tumor progression in vivo that were demonstrated by previous studies and provides the potential of daily intake of moderate splicing inhibitors to prevent cancer development. [Display omitted] •Food-derived compounds, apigenin and luteolin, modulate mRNA splicing•The treatment of these flavonoids causes numerous alternative splicing events•Splicing of introns with weak splice sites tend to be inhibited by these flavonoids•Tumorigenic cells are more sensitive to these flavonoids than non-tumorigenic cells Molecular Biology